Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension.

Remková, A ; Kratochvíl'ová, H ; et al.

In: Journal of human hypertension, Jg. 22 (2008-05-01), Heft 5, S. 338-45

Online academicJournal

Zugriff:

Volltext (PDF)

The aim of the study was to investigate the effect of therapy by perindopril or telmisartan on endothelial/platelet function and on coagulation/fibrinolysis in 20 and 16 hypertensive patients, respectively. The measurements were carried out before and after 1 month of therapy. Both systolic blood pressure and diastolic blood pressure were reduced (P<0.001) or normalized due to each therapy. Plasma thrombomodulin (TM) and von Willebrand factor (vWF) as indicators of endothelial dysfunction, plasma beta-thromboglobulin (betaTG), platelet factor 4 (PF4), soluble P-selectin (sPsel) and soluble glycoprotein V (sGpV) as indicators of in vivo platelet activation, plasminogen activator inhibitor type 1 (PAI-1) antigen and tissue type plasminogen activator (tPA) antigen as markers of fibrinolytic activity, soluble endothelial protein C receptor (sEPCR) as a new marker of hypercoagulation and fibrinogen level as a known risk factor for vascular changes were investigated. A decrease of plasma vWF, sPsel, sGpV, PAI-1 and tPA antigen level (P<0.05, respectively) after 1 month of therapy by perindopril was observed. On the other hand, a decrease of plasma sEPCR and fibrinogen level (P<0.05, respectively) after 1 month of therapy by telmisartan was found. We failed to find changes of plasma TM, betaTG and PF4 due to any therapy investigated. The additional beneficial 'antithrombotic' effects of the renin-angiotensin system targeting agents (vasculoprotective, anti-platelet and profibrinolytic effects of perindopril and anticoagulant/rheological effects of telmisartan) may be important in terms of the favourable role of antihypertensive drugs in cardiovascular morbidity.

Titel:	Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension.
Autor/in / Beteiligte Person:	Remková, A ; Kratochvíl'ová, H ; Durina, J
Link:	Volltext (PDF)
Zeitschrift:	Journal of human hypertension, Jg. 22 (2008-05-01), Heft 5, S. 338-45
Veröffentlichung:	<2003->: London : Nature Publishing Group ; <i>Original Publication</i>: Houndmills, Basingstoke, Hampshire, UK : Scientific & Medical, Macmillan Press, c1987-, 2008
Medientyp:	academicJournal
ISSN:	0950-9240 (print)
DOI:	10.1038/sj.jhh.1002328
Schlagwort:	Adult Aged Aged, 80 and over Angiotensin II Type 1 Receptor Blockers therapeutic use Antihypertensive Agents therapeutic use Benzimidazoles therapeutic use Benzoates therapeutic use Blood Coagulation drug effects Blood Platelets drug effects Case-Control Studies Chi-Square Distribution Female Fibrinolysis drug effects Humans Male Middle Aged Perindopril therapeutic use Statistics, Nonparametric Telmisartan Angiotensin II Type 1 Receptor Blockers pharmacology Antihypertensive Agents pharmacology Benzimidazoles pharmacology Benzoates pharmacology Biomarkers blood Hypertension drug therapy Perindopril pharmacology Renin-Angiotensin System drug effects Thrombosis prevention & control
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [J Hum Hypertens] 2008 May; Vol. 22 (5), pp. 338-45. <i>Date of Electronic Publication: </i>2008 Feb 28. MeSH Terms: Angiotensin II Type 1 Receptor Blockers / pharmacology ; Antihypertensive Agents / pharmacology ; Benzimidazoles / pharmacology ; Benzoates / pharmacology ; Biomarkers / blood ; Hypertension / drug therapy ; Perindopril / pharmacology ; Renin-Angiotensin System / drug effects ; Thrombosis / *prevention & control ; Adult ; Aged ; Aged, 80 and over ; Angiotensin II Type 1 Receptor Blockers / therapeutic use ; Antihypertensive Agents / therapeutic use ; Benzimidazoles / therapeutic use ; Benzoates / therapeutic use ; Blood Coagulation / drug effects ; Blood Platelets / drug effects ; Case-Control Studies ; Chi-Square Distribution ; Female ; Fibrinolysis / drug effects ; Humans ; Male ; Middle Aged ; Perindopril / therapeutic use ; Statistics, Nonparametric ; Telmisartan Substance Nomenclature: 0 (Angiotensin II Type 1 Receptor Blockers) ; 0 (Antihypertensive Agents) ; 0 (Benzimidazoles) ; 0 (Benzoates) ; 0 (Biomarkers) ; U5SYW473RQ (Telmisartan) ; Y5GMK36KGY (Perindopril) Entry Date(s): Date Created: 20080229 Date Completed: 20081021 Latest Revision: 20181201 Update Code: 20240513

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.